Available IPD datapackage for study 'A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMA™) in Combination With Pemetrexed (Alimta®) Versus Pemetrexed Alone in Patients With Locally-Advanced or Metastatic NSCLC'

Non-small cell lung cancer (NSCLC) can be treated with drugs that kill tumour cells, stop
them from dividing, or stop the growth of the blood supply that cancers need to grow and
spread. Clinical research has shown that drugs that inhibit vascular endothelial growth
factor receptor (VEGFR) or epidermal growth factor receptor (EGFR) signalling can increase
overall survival in patients with advanced non-small cell lung cancer (NSCLC). Preclinical
studies have shown that vandetanib (ZD6474) is an inhibitor of both VEGFR and EGFR
signalling. Giving vandetanib may therefore inhibit the growth of cancer cells by blocking
their blood supply and by stopping them from dividing. This lung cancer study is to
investigate if adding vandetanib to Alimta (pemetrexed) is more effective than Alimta
(pemetrexed) alone.